Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142627 |
| CAS No | NA |
| Mol.F. | C14H19ClN2O3 |
| Mol.Wt. | 298.8g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142628 |
| CAS No | NA |
| Mol.F. | C13H16Cl2N2O2 |
| Mol.Wt. | 303.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142629 |
| CAS No | NA |
| Mol.F. | C13H17ClN2O2 |
| Mol.Wt. | 268.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142630 |
| CAS No | NA |
| Mol.F. | C13H17BrN2O2 |
| Mol.Wt. | 313.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142631 |
| CAS No | NA |
| Mol.F. | C12H13ClN2O4S |
| Mol.Wt. | 316.8 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142632 |
| CAS No | NA |
| Mol.F. | C13H17ClN2O2 |
| Mol.Wt. | 268.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142633 |
| CAS No | NA |
| Mol.F. | C13H16Cl2N2O2 |
| Mol.Wt. | 303.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142634 |
| CAS No | NA |
| Mol.F. | C13H17ClN2O3 |
| Mol.Wt. | 284.74 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142635 |
| CAS No | NA |
| Mol.F. | C21H32N6O4 |
| Mol.Wt. | 432.53 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142636 |
| CAS No | NA |
| Mol.F. | C33H50N10O4 |
| Mol.Wt. | 650.83 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142637 |
| CAS No | NA |
| Mol.F. | C34H51N7O6 |
| Mol.Wt. | 653.83 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142638 |
| CAS No | NA |
| Mol.F. | C9H12N2O3 |
| Mol.Wt. | 196.21 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142639 |
| CAS No | NA |
| Mol.F. | C11H10N4O3 |
| Mol.Wt. | 246.23 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142640 |
| CAS No | NA |
| Mol.F. | C25H40N6O4 |
| Mol.Wt. | 488.63 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142641 |
| CAS No | NA |
| Mol.F. | C23H36N6O4 |
| Mol.Wt. | 460.58 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N01426412 |
| CAS No | NA |
| Mol.F. | C13H14ClN5O4 |
| Mol.Wt. | 339.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |